Ferric citrate hydrate, a new phosphate binder, prevents the complications of secondary hyperparathyroidism and vascular calcification

American Journal of Nephrology

Volumn 37, Issue 4, 2013, Pages 346-358

  Iida, Akio ^a   Kemmochi, Yusuke ^a   Kakimoto, Kochi ^a   Tanimoto, Minako ^a   Mimura, Takayuki ^a   Shinozaki, Yuichi ^a   Uemura, Atsuhiro ^a   Matsuo, Akira ^a   Matsushita, Mutsuyoshi ^a   Miyamoto, Ken Ichi ^b  

^a JAPAN TOBACCO INC   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Ferric citrate hydrate; Hyperphosphatemia; Phosphate absorption; Phosphate binder

Indexed keywords

ADENINE; CALCIUM; CALCIUM CARBONATE; FERRIC CITRATE; PARATHYROID HORMONE; PHOSPHORUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; ARTICLE; BLOOD VESSEL CALCIFICATION; BONE DISEASE; BONE FIBROSIS; BONE MALFORMATION; BONE MINERAL; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DIET; DISEASE SEVERITY; FECES; FEEDING; FEMUR; FIBROSIS; HISTOPATHOLOGY; HYPERCALCEMIA; HYPERPHOSPHATEMIA; KIDNEY TUBULE ABSORPTION; MALE; NONHUMAN; OSTEOID; PARATHYROID GLAND; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROID HYPERPLASIA; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RAT; SECONDARY HYPERPARATHYROIDISM; SERUM; URINARY EXCRETION;

EID: 84875681406     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000348805     Document Type: Article

References (31)

1. de Francisco AL: Secondary hyperparathyroidism: review of the disease and its treatment. Clin Ther 2004; 26: 1976-1993.
2. Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS, McAllister CJ, Budoff MJ, Salusky JB, Kopple JD: Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: 771-780.
3. Shigematsu T, Kono T, Satoh K, Yokoyama K, Yoshida T, Hosoya T, Shirai K: Phosphate overload accelerates vascular calcium deposition in end-stage renal disease patients. Nephrol Dial Transplant 2003; 18:iii86-iii89.
4. Slatopolsky E, Brown A, Dusso A: Pathogenesis of secondary hyperparathyroidism. Kidney Int Suppl 1999; 73:S14-S19.
5. Chertow GM, Raggi P, Chasan-Taber S, Bommer J, Holzer H, Burke SK: Determinants of progressive vascular calcification in haemodialysis patients. Nephrol Dial Transplant 2004; 19: 1489-1496.
6. Chertow GM, Burke SK, Raggi P: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-252.
7. Raggi P, Vukicevic S, Moyses RM, Wesseling K, Spiegel DM: Ten-year experience with sevelamer and calcium salts as phosphate binders. Clin J Am Soc Nephrol 2010; 5(suppl 1):S31-S40.
8. Toussaint ND, Lau KK, Polkinghorne KR, Kerr PG: Attenuation of aortic calcification with lanthanum carbonate versus calciumbased phosphate binders in haemodialysis: a pilot randomized controlled trial. Nephrology (Carlton) 2011; 16: 290-298.
9. Salusky IB, Goodman WG, Sahney S, Gales B, Perilloux A, Wang HJ, Elashoff RM, Juppner H: Sevelamer controls parathyroid hormoneinduced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols. J Am Soc Nephrol 2005; 16: 2501-2508.
10. Katsumata K, Kusano K, Hirata M, Tsunemi K, Nagano N, Burke SK, Fukushima N: Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats. Kidney Int 2003; 64: 441-450.
11. Damment S, Secker R, Shen V, Lorenzo V, Rodriguez M: Long-term treatment with lanthanum carbonate reduces mineral and bone abnormalities in rats with chronic renal failure. Nephrol Dial Transplant 2011; 26: 1803-1812.
12. Neven E, Dams G, Postnov A, Chen B, De Clerck N, De Broe ME, D'Haese PC, Persy V: Adequate phosphate binding with lanthanum carbonate attenuates arterial calcification in chronic renal failure rats. Nephrol Dial Transplant 2009; 24: 1790-1799.
13. Hergesell O, Ritz E: Stabilized polynuclear iron hydroxide is an efficient oral phosphate binder in uraemic patients. Nephrol Dial Transplant 1999; 14: 863-867.
14. Hsu CH, Patel SR, Young EW: New phosphate binding agents: ferric compounds. J Am Soc Nephrol 1999; 10: 1274-1280.
15. Yang WC, Yang CS, Hou CC, Wu TH, Young EW, Hsu CH: An open-label, crossover study of a new phosphate-binding agent in haemodialysis patients: ferric citrate. Nephrol Dial Transplant 2002; 17: 265-270.
16. Block GA, Brillhart SL, Persky MS, Amer A, Slade AJ: Efficacy and safety of SBR759, a new iron-based phosphate binder. Kidney Int 2010; 77: 897-903.
17. Chen JB, Chiang SS, Chen HC, Obayashi S, Nagasawa M, Hexham JM, Balfour A, Junge G, Akiba T, Fukagawa M: Efficacy and safety of SBR759, a novel calcium-free, iron(III)-based phosphate binder, in Asian patients undergoing hemodialysis: a 12-week, randomized, open-label, dose-titration study versus sevelamer hydrochloride. Nephrology (Carlton) 2011; 16: 743-750.
18. Geisser P, Philipp E: PA21: a novel phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease. Clin Nephrol 2010; 74: 4-11.
19. Sinsakul M, Sika M, Koury M, Shapiro W, Greene T, Dwyer J, Smith M, Korbet S, Lewis J: The safety and tolerability of ferric citrate as a phosphate binder in dialysis patients. Nephron Clin Pract 2012; 121:c25-c29.
20. Umanath K, Sika M, Niecestro R, Connelly C, Schulman G, Koury MJ, Lewis JB, Dwyer JP, Collaborative Study Group: Rationale and study design of a three-period, 58-week trial of ferric citrate as a phosphate binder in patients with ESRD on dialysis. Hemodial Int 2013; 17: 67-74.
21. Yokoyama K, Hirakata H, Akiba T, Sawada K, Kumagai Y: Effect of oral JTT-751 (ferric citrate) on hyperphosphatemia in hemodialysis patients: results of a randomized, doubleblind, placebo-controlled trial. Am J Nephrol 2012; 36: 478-487.
22. Kawata T, Nagano N, Obi M, Miyata S, Koyama C, Kobayashi N, Wakita S, Wada M: Cinacalcet suppresses calcification of the aorta and heart in uremic rats. Kidney Int 2008; 74: 1270-1277.
23. Fleming RE, Ponka P: Iron overload in human disease. N Engl J Med 2012; 366: 348-359.
24. Cullen EI, Mandella R, Auletta C, Niecestro R: A 28-day toxicity study of KRX-0502 (ferric citrate) in rats by dietary administration. Soc Toxicol Abstract 2008; 1924.
25. Henley C, Davis J, Miller G, Shatzen E, Cattley R, Li X, Martin D, Yao W, Lane N, Shalhoub V: The calcimimetic AMG 641 abrogates parathyroid hyperplasia, bone and vascular calcification abnormalities in uremic rats. Eur J Pharmacol 2009; 616: 306-313.
26. Nagano N, Miyata S, Obana S, Eto N, Fukushima N, Burke SK, Wada M: Renal mineral handling in normal rats treated with sevelamer hydrochloride (Renagel), a noncalcemic phosphate binder. Nephron 2001; 89: 321-328.
27. Damment SJ: Pharmacology of the phosphate binder, lanthanum carbonate. Ren Fail 2011; 33: 217-224.
28. Alfrey AC, LeGendre GR, Kaehny WD: The dialysis encephalopathy syndrome. Possible aluminum intoxication. N Engl J Med 1976; 294: 184-188.
29. Parsons V, Davies C, Goode C, Ogg C, Siddiqui J: Aluminium in bone from patients with renal failure. Br Med J 1971; 4: 273-275.
30. Elliott HL, Dryburgh F, Fell GS, Sabet S, Macdougall AI: Aluminium toxicity during regular haemodialysis. Br Med J 1978; 1: 1101-1103.
31. Slanina P, Frech W, Ekstrom LG, Loof L, Slorach S, Cedergren A: Dietary citric acid enhances absorption of aluminum in antacids. Clin Chem 1986; 32: 539-541.